ERBB2 and breast cancer: In contrast to previous studies using human ERBB2-positive breast cancer cell lines3, our murine cell lines were derived from littermates, have an identical genetic background, the same mutation and acquired lapatinib resistance in vivo (with normal gland architecture, tumor microenvironment, immune system status), and therefore should better reflect the resistance mechanisms encountered in patients in the clinic.